0.85Open0.55Pre Close72 Volume3.10K Open Interest15.00Strike Price2.95KTurnover155.04%IV56.82%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.2167Delta0.0707Gamma23.11Leverage Ratio-0.0227Theta0.0013Rho5.01Eff Leverage0.0079Vega
Cybin Stock Discussion
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$
$NVIDIA (NVDA.US)$ $Tesla (TSLA.US)$ $SoFi Technologies (SOFI.US)$
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN)reported groundbreaking 12-month efficacy data from its Phase 2 study of CYB003 for major depressive disorder (MDD). After two 16mg doses administered three weeks apart, 100% of participants were responsive to treatment, with 71% in remission at 12 months. The study showed a ~23-point reduction in MADRS depression s...
EXCLUSIVE: Cybin Tells Benzinga Co. Announces Grant Of First U.S Composition of Matter Patent N Support Of Its CYB005 Phenethylamines Program
No comment yet